NL-OMON25125招募中不适用
Tofacitinib: salvage therapy for patients with RCDII - a pilot study
Amsterdam UMC, location VU University Medical Center0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult patients ≥ 18 years old
- •2. Given informed consent
排除标准
- •1. Diagnosis of RCDI, EATL
- •2. Presence of any of the following diagnosis:
研究者
相似试验
进行中（未招募）
1 期
Research with the drug tofacitinib for patients with refractory celiac disease type IIRefractory celiac disease type IIEUCTR2018-001678-10-NLVU Medical Center5
招募中
2 期
Tofacitinib: salvage therapy for patients with RCDII - a pilot studygluten intolerancerefractory celiac disease type II1002532110017969NL-OMON52502Vrije Universiteit Medisch Centrum4
已完成
不适用
Tofacitinib therapy for rheumatoid arthritis : a direct comparison study between biologic-naive and experienced patients.Rheumatoid arthritisJPRN-UMIN000035854ational Hospital Organization100
已完成
2 期
Tofacitinib in the treatment of chronic, recurrent and/or antibiotic refractory pouchitis: a multi-omics approachinflammation of the pouch reservoir10017969PouchitisNL-OMON52963Academisch Medisch Centrum13
进行中（未招募）
1 期
Treatment of refractory pouchitis with tofacitinibEUCTR2020-002695-12-NLAmsterdam UMC, location AMC12